Expression and characterisation of recombinant human CD48 and isolation of a human anti-CD48 monoclonal antibody by phage display

Journal of Chemical Technology and Biotechnology

Volumn 80, Issue 7, 2005, Pages 782-795

  Wei, Jiewei ^a   Chin, David Y ^a   Catzel, Dallia ^a   Pera, Natasha ^a   Mahler, Stephen M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

CD48; Human monoclonal antibodies; Luekaemia; Lymphoma; Phage display

Indexed keywords

CELLS; GENES; PROTEINS; SURFACE PLASMON RESONANCE;

BIOPANNING; GLYCOPROTEINS; RAJI CELLS; WHITE BLOOD CELLS;

ANTIBODIES;

CD48 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY N2A; RECOMBINANT ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

MEDICAL APPLICATION;

ANIMAL CELL; ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG PROTEIN BINDING; FLOW CYTOMETRY; GENE LIBRARY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; RAJI CELL; SURFACE PLASMON RESONANCE;

CRICETULUS GRISEUS;

EID: 21344433488     PISSN: 02682575     EISSN: None     Source Type: Journal    
DOI: 10.1002/jctb.1238     Document Type: Article

References (74)

1. Glennie MJ and Johnson PWM, Clinical trials of antibody therapy. Immunol Today 21:403-410 (2000).
2. Goldstein G, Fuccello AJ, Norman DJ, Shield CF, Colvin RB and Cosimi AB, OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42:507-511 (1986).
3. Norman DJ, Chatenoud L, Cohen D, Goldman M and Shield CF, Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 25:89-92 (1993).
4. Waldmann TA, Monoclonal antibodies in diagnosis and therapy. Science 252:1657-1662 (1991).
5. Weiner LM and Carter P, The rollercoaster ride to anti-cancer antibodies. Nature Biotechnology 21:510-511 (2003).
6. Shan D, Ledbetter JA and Press OW, Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644-1652 (1998).
7. McCafferty J, Griffiths D, Winter G and Chiswell DJ, Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552-554 (1990).
8. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruine AP, Arends JW and Hoogenboom HR, A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biological Chemistry 274:18 218-18 230 (1999).
9. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG, Munoz-O'Regan D, O'Donnell SL, Lapachet ESG, Bengoechea T, Fishwild DM, Carmack CE, Kay RM and Huszar D, Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856-859 (1994).
10. Mendez MJ, Green LL, Corvalan JRF, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CMN, Abderrahim H, Kirschembaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Finer MH, Davis CG, Zsebe M and Jakovovits A, Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genetics 15:146-156 (1997).
11. Hanes J, Jermutus L, Weber-Bornhauser S and Bosshard HR, Ribosome display efficiently selects and evolves high affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci 95:14 130-14 135 (1998).
12. Hanes J, Schaffitzel C, Knappik A and Pluckthun A, Picomolar affinity antibodies from a fully synthetic naïve library selected and evolved by ribosomal display. Nature Biotechnology 18:1287-1292 (2000).
13. Coia G, Pontes-Braz L, Nuttall SD, Hudson PJ and Irving RA, Panning and selection of proteins using ribosome display. J Immunol Methods 254:191-197 (2001).
14. Johnsson K and Ge L, Phage display of combinatorial peptide and protein libraries and their applications in biology and chemistry. Current Topics in Microbiology Immunol 243:87-105 (1999).
15. Moshitch-Moshkovitz S, Heldman Y, Yayon A and Katchalski-Katzir E, Sorting polyclonal antibodies into funtionally distinct fractions using peptide phage display: a library on top of a library. J Immunol Methods 242:183-191 (2000).
16. Li M, Applications of display technology in protein analysis. Nature Biotechnology 18:1251-1256 (2000).
17. Aujame L, Geoffroy F and Sodoyer R, High affinity human antibodies by phage display. Human Antibodies 8:155-168 (1997).
18. Hufton SE, Moerkerk PT, Meulemans EV, de Bruine A, Arends JW and Hoogenboom HR, Phage display of cDNA repertoire: the pVI display system and its application for the selection of immunogenic ligands. J Immunol Methods 231:39-51 (1999).
19. Flores-Flores C, Nissim A, Shochat S and Soreq H, Development of human antibody fragments directed towards synaptic acetylcholinesterase using a semi-synthetic phage display library. J Neural Transmission 62:165-179 (2002).
20. van Beijnum JR, Moerkerk PT, Gerbers AJ, de Bruine AP, Arends JW, Hoogenboom HR and Hufton SE, Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 101: 118-127 (2002).
21. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD and Winter G, By-passing immunization: human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581-597 (1991).
22. Dall'Acqua W and Carter P, Antibody engineering. Current Opinion in Structural Biology 8:443-450 (1998).
23. Thompson JE, Vaughan TJ, Williams AJ, Wilton J, Johnson KS, Bacon L, Green JA Field R, Ruddock S, Martins M, Pope AR, Tempest PR and Jackson RH, A fully human antibody neutralising biologically active human TGFβ2 for use in therapy. J Immunol Methods 227:17-29 (1999).
24. Jespers LS, Robert A, Maher SM, Winter G and Hoogenboom HR, Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Bio/Technology 12:899-903 (1994).
25. Scheinfeld N, Adalimumab (Humira): a review. J Drugs in Dermatology 2:375-377 (2003).
26. Maloney DZ, Grillo-Lopez AJ and White CA, IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195 (1997).
27. Reff ME, Carner K and Chambers KS, Depletion of B cells in vivo by a chimeric mouse monoclonal antibody to CD20. Blood 83:435-445 (1994).
28. Scheinber DA, Straus DJ, Yeh SD, Divgi C, Garin-Chesa P, Granham M, Pentlow K, Coit D, Oettgen HF and Old LJ, A phase I toxicity pharmacology and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 8:792-803 (1990).
29. Vlasveld LT, Hekman A, Vythdreese FA, Melief CJM, Sein JJ, Voordouw AC, Dellemijn TAM and Rankin EM, Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother 40:37-47 (1995).
30. Osterborg A, Dyer M, Bunjes D, Pangali GA, Bastion Y, Catovsky D and Mellstedt H, Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia.J Clin Oncol 15:1567-1574 (1997).
31. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P and Shen D, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals Oncol 9:995-1001 (1998).
32. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programme. J Clin Oncol 16:2825-2833 (1998).
33. + large granular lymphocytes triggered by a tumor-expressed activating ligand. Leukemia 16:855-860 (2002).
34. Sun H, Norris BJ, Atkinson K, Biggs JC and Smith GM, Preclinical antitumor activity of an antibody against the leukocyte antigen CD48. Clin Cancer Res 4:895-900 (1998).
35. Korinek V, Stefanova I, Angelisova P, Hilgert I and Horejsi V, The human leucocyte antigen CD48 (MEM-102) is closely related to the activation marker Blast-1. Immunogenetics 33:108-112 (1991).
36. Sandrin MS, Mouhtouris E, Vaughan HA, Warren HS and Parish CR, CD48 is a low affinity ligand for human CD2. J Immunol 151:4606-4613 (1993).
37. Davis SJ and van der Merwe PA, The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today 17:177-187 (1996).
38. de la Fuente MA, Pizcueta P, Nadal M, Bosch J and Engel P, CD84 leukocyte antigen is a new member of the Ig superfamily. Blood 90:2398-2405 (1997).
39. Nakajima H and Colonna M, 2B4: an NK cell activating receptor with unique specificity and signal transduction mechanism. Human Immunol 61:39-43 (2000).
40. Mulvey MA and Hultgren SJ, Bacterial spelunkers. Science 289:732-733 (2000).
41. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA and Barclay AN, 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 188:2083-2090 (1998).
42. Kubin MZ, Parshley DL, Din W, Waugh JY, Davis-Smith T, Smith CA, Macduff BM, Armitage RJ, Chin W, Cassiano L, Borges L, Petersen M, Trinchieri G and Goodwin RG, Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48. European J Immunol 29:3466-3477 (1999).
43. Colonna M, Nakajima H, Navarro F and Lopez-Botet M, A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukocyte Biology 66:375-381 (2000).
44. Colonna M, Nakajima H and Cella M, Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. J Leukocyte Biology 66:718-722 (1999).
45. Kambayashi T, Assarsson E, Chambers BJ and Ljunggren HG, Cutting edge: regulation of CD8+ T cell proliferation by 2B4/CD48 interactions. J Immunol 167:6706-6710 (2001).
46. Greenaway S, Henniker AJ, Walsh M and Bradstock KF, A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphomatic leukemia. Leukemia and Lymphoma 13:323-331 (1994).
47. Sun H, Biggs JC and Smith GM, Antitumour activity of a chimeric antibody against the leucocyte antigen CD48. Cancer Immunol Immunother 48:595-602 (2000).
48. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D and Winter G, Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 13:692-698 (1994).
49. Vaughan HA, Thompson CH, Sparrow RL and McKenzie IFC, Hu Ly-m3 - a human leukocyte antigen. Transplantation 36:446-450 (1983).
50. Henniker AJ, Bradstock KF, Grimsley P and Atkinson MK, A novel non-lineage antigen on human leucocytes: characterization with two CD-48 monoclonal antibodies. Disease Markers 8:179-190 (1990).
51. Evan GI, Lewis GK, Ramsay G and Bishop JM, Isolation of monoclonal antibodies specific for human c-myc protooncogene product. Mol Cell Biol 5:3610-3616 (1985).
52. Vaughan HA, Henning MM, Purcell DFJ, McKenzie IFC and Sandrin MS, The isolation of cDNA clones for CD48. Immunogenetics 33:112-117 (1991).
53. Yates JL, Warren N and Sugden B, Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313:812-815 (1985).
54. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD and Winter G, By-passing immunisation: human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581-597 (1991).
55. Hoogenboom HR and Winter G, By-passing immunisation human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 227:381-388 (1992).
56. Mahler SM, Marquis CP, Brown G, Roberts A and Hoogenboom HR, Cloning and expression of human V-genes derived from phage display libraries as fully assembled human anti-TNFa monoclonal antibodies. Immunotechnology 3:31-43 (1997).
57. Johnsson B, Lofas S and Lindquist G, Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem 198:268-277 (1991).
58. Karlsson R and Falt A, Kinetic and concentration analysis using BIA technology. J Immunol Methods 200:121-133 (1997).
59. Joss L, Morton TA, Doyle ML and Myszka DG, Interpreting kinetic rate constants from optical biosensor data recorded on a decaying surface. Analytical Biochem 261:203-210 (1998).
60. Watters JM, Telleman P and Junghans RP, An optimized method for cell-based phage display panning. Immunotechnology 3:21-29 (1997).
61. Mutuberria R, Hoogenboom HR, van der Linden E, de Bruine AP and Roovers RC, Model systems to study the parameters determining the success of phage antibody selections on complex antigens. J Immunol Methods 231:65-81 (1999).
62. Hoogenboom HR, Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends in Biotechnology 15:62-70 (1997).
63. Furukawa Y, Tamura H and Ikezawa H, Mutational analysis of the COOH-terminal hydrophobic domain of bovine liver 5′-nucleotidase as a signal for glycosylphophatidylinositol (GPI) anchor attachment. Biochim Biophys Acta 1190:273-278 (1994).
64. Moran P and Caras IW, Proteins containing an uncleaved signal for glycophosphatidylinositol membrane anchor attachment are retained in post-ER compartment. J Cell Biol 119:763-772 (1992).
65. Field MC, Moran P, Li W, Keller GA and Caras IW, Retention and degradation of proteins containing an uncleaved glycosylphosphatidylinositol signal. J Biol Chem 269:10 830-10 837 (1994).
66. Yang J, Tiong J, Kennard M and Jefferies WA, Deletion of the GPI pre-anchor sequence in human p97-a general approach for generating the soluble form of GPI-linked proteins. Protein Expr Purif 34:28-48 (2004).
67. Killeen N, Moessner R, Arvieux J, Willis A and Williams AF, The MRC OX-45 antigen of rat leukocytes and endothelium is in a subset of the immunoglobulin superfamily with CD2, LFA-3 and carcinoembryonic antigens. EMBO J 7:3087-3091(1988).
68. Staunton DE, Fisher RC, LeBeau MM, Lawrence JB, Barton DE, Francke U, Dustin M and Thorley-Lawson DA, Blast-1 possesses a glycosyl-phospatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX45, and maps to chromosome 1q21-23. J Exp Med 169:1087-1099 (1989).
69. Staunton DE and Thorley-Lawson DA, Molecular cloning of the lymphocyte activation marker Blast-1. EMBO J 6:3695-3701 (1987).
70. Tomlinson IM, Walter JD, Llewelyn MB and Winter G, The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 227:776-798 (1992).
71. Tangye SG, Phillips JH and Lanier LL, The CD2-subset of the Ig superfamily of cell surface molecules: receptor ligand pairs expressed by NK cells and other immune cells. Seminars in Immunol 12:149-157 (2000).
72. Fromant M, Blanquet S and Plateau P, Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction. Analytical Biochem 224:347-353 (1995).
73. Daugherty PS, Chen G, Iverson BL and Georgiou G, Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc Natl Acad Sci 97:2029-2034 (2000).
74. Low NM, Holliger P and Winter G, Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J Mol Biol 260:359-368 (1996).